DOCSLIB.ORG

And Generator-Based Positron Emission Tomography (PET) - Radiopharmaceuticals: Challenges and Barriers in Receiving Market Authorisation”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
And Generator-Based Positron Emission Tomography (PET) - Radiopharmaceuticals: Challenges and Barriers in Receiving Market Authorisation” Aus der Klinik und Poliklinik für Nuklearmedizin der Ludwig-Maximilians- Universität München Direktor: Prof. Dr. med. Peter Bartenstein “Innovation through Cyclotron/ and Generator-based Positron Emission Tomography (PET) - Radiopharmaceuticals: Challenges and Barriers in Receiving Market Authorisation” Dissertation zum Erwerb des Doktorgrades der Humanbiologie an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München vorgelegt von Georg Konwalinka aus Rum in Tirol (Österreich) Jahr 2019 2 Mit Genehmigung der Medizinischen Fakultät der Universität München Berichterstatter: Prof. Dr. Peter Bartenstein Mitberichterstatter: Prof. Dr. Clemens Cyran Prof. Dr. Claus Belka Dekan: Prof. Dr. med. dent. Reinhard Hickel Tag der mündlichen Prüfung: 21.10.2019 3 Eidesstattliche Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit eigenständig und ohne fremde Hilfe angefertigt habe. Textpassagen, die wörtlich oder dem Sinn nach auf Publikationen oder Vorträgen anderer Autoren beruhen, sind als solche kenntlich gemacht. Die Arbeit wurde bisher keiner anderen Prüfungsbehörde vorgelegt und auch noch nicht veröffentlicht. München, 06.06.2019 Georg Konwalinka 4 „All I know is that I know nothing.“ (Socrates, * ~ 469 before Chr, † 399 AD) A very special thanks to my doctoral supervisor Professor. Dr. med. Peter Bartenstein with whom I was able to work on an innovative and interesting topic. I thank him for his continuous dedicated support, which, despite his abundance of everyday tasks, had not to wait. I want to thank him for many interesting discussions, his visionary thinking and the effort to teach me complex issues. The collaboration with Prof. Bartenstein has challenged and encouraged me in my scientific and personal development. I would also like to give thanks to my colleagues from the various disciplines, who have pointed out new perspectives in the critical discussion and have encouraged me in my endeavour to write this thesis. Many thanks also to the numerous internationally recognized experts in the field nuclear medicine from university / medical research centres, practitioners from well-known clinic institutions, scientists in the various industries and also the experts of public law institutions. They offered me their free time to conduct these interviews, the basis to ultimately finish this thesis. Furthermore I want to thank Dr. Leonie Beyer who supported me with an excellent proof-reading of the scientific medical part, and Miss Egg, who has checked grammar and spelling of this extensive work several times. My special thanks to my friends and my family. They accompanied me during this journey and always supported me, in beautiful moments but also in times of doubt. 5 Table of ContentsTable of Figures 9 List of Tables ............................................................................................................................................ 10 1.1 Introduction to the Research Topic: .................................................................. 12 1.2 Statement of the Research Problem: ................................................................ 13 1.3 Statement of the Purpose of this Study ............................................................ 15 1.4 Methodology ..................................................................................................... 16 1.4.1 Quantitative Research – Focused Literature Review ......................................................... 17 1.4.2 Qualitative Research – Expert Interviews .......................................................................... 18 2 Role of Nuclear Medicine in Oncology ........................................................................................... 25 2.1 Theranostics – combining diagnostics and therapy .......................................... 26 2.2 Case 1 - Somatostatin Receptor Scintigraphy in Neuroendocrine Tumours (NETs) 27 2.2.1 Epidemiological data .......................................................................................................... 28 2.2.2 Diagnostic workup of NETs –Biochemical Markers ........................................................... 29 2.2.3 Therapy Options in the Treatment of NETs ....................................................................... 31 2.2.4 Specific Targeting via Somatostatin Analogues - Imaging ................................................. 32 2.2.5 Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues ............... 40 2.3 Case II- Radionuclide Imaging and Therapy in Prostate carcinoma ................... 47 3 Current Challenges in the Radiopharmaceutical Industry – A Case Story of DOTATATE ............... 65 3.1 The long Way to Market Authorisation ............................................................. 67 I. Economic and Market-related Challenges ......................................................................... 68 II. Research and Development Challenges ............................................................................ 69 III. Regulation and Marketing Authorisation Challenges ........................................................ 69 IV. Reimbursement and Revenue Planning Challenges .......................................................... 69 V. Different goals between the Scientific Community and Investors/Industry ..................... 69 VI. Special Manufacturing, Distribution and Handling of Radiopharmaceuticals ................... 69 3.2 Market Size and Potential .................................................................................. 71 3.2.1 The Radiopharmaceutical Market Potential and Investors Interest ................................. 72 3.3 Barriers and Challenges associated with Research and Development (R&D): .. 74 3.3.1 High Development Costs and Low Chances of Success – Conventional Drugs .................. 74 3.3.2 High Development Costs and Low Chances of Success – RP Imaging Markers ................. 76 3.4 Intellectual Property Right Issues ...................................................................... 78 3.4.1 Academic Institutions and Intellectual Property Rights .................................................... 79 3.5 Experimental RPs are not Evolving .................................................................... 81 3.5.1 Imaging Markers are not Validated ................................................................................... 83 3.6 Regulation and Marketing Authorisation .......................................................... 85 3.6.1 Challenges in the Regulatory and Safety Approval Process .............................................. 85 3.6.2 Regulatory Approval Process in Medical Imaging and Radiopharmaceuticals .................. 86 3.7 Uncertainty in Reimbursement and Revenue Planning..................................... 90 3.7.1 The challenge of rising healthcare costs ............................................................................ 90 3.7.2 Reimbursement – The Change of Systems ........................................................................ 92 3.7.3 Reimbursement of PET (PET/CT) Procedures and Imaging Biomarkers in Germany ........ 93 3.7.4 Reimbursement as an area of uncertainty ........................................................................ 95 3.8 Different Goals between Scientific Community and Investors/ Industry .......... 96 3.8.1 Different goals in Industry- and Academic Research ......................................................... 96 3.9 Limited Knowledge in the Scientific Community, outside the Nuclear Medicine Community .......................................................................................................................... 98 3.9.1 The Effect of Clinical Practice Guidelines on Nuclear Medicine Awareness ..................... 99 6 3.10 Special Manufacturing, Distribution and Handling of Radiopharmaceuticals: 100 3.10.1 Manufacturing: ................................................................................................................ 100 3.10.2 The Challenge of Distribution and Logistics .................................................................... 101 3.10.3 Handling: .......................................................................................................................... 101 4 Empirical Results:.......................................................................................................................... 103 4.1 The Role of Imaging ......................................................................................... 103 4.2 Radiopharmaceuticals ..................................................................................... 106 4.2.1 Issue with Reimbursement .............................................................................................. 108 4.2.2 Challenge with Regulations ............................................................................................. 113 4.2.3 The Issue with Market Potential ..................................................................................... 116 4.2.4 The Issue with Research and Development .................................................................... 120 4.2.5 The Issue with Intellectual Property Rights (IPR): ........................................................... 124 4.2.6 The Issue with Manufacturing, Distribution and Handling ............................................. 129 4.3 Diagnostic Radiopharmaceuticals used as Companion Diagnostics ................ 132 4.3.1 The Stakeholder´s Definitions of
Load more

Recommended publications
  • List Item Withdrawal Assessment Report for Folcepri
    20 March 2014 EMA/CHMP/219148/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Folcepri International non-proprietary name: etarfolatide Procedure No.: EMEA/H/C/002570/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. This AR reflects the CHMP opinion on 20 March 2014, which originally recommended to approve this medicine. The recommendation was conditional to the results of the on-going confirmatory study EC-FV-06. Before the marketing authorisation was granted by the EC, the results of this study became available and did not support the initial recommendation. Subsequently, the company decided to withdraw the application and not to pursue any longer the authorisation for marketing this product. The current report does not include the latest results of this study as the withdrawal of the application did not allow for the CHMP to revise its opinion in light of the new data. For further information please refer to the Q&A which followed the company’s withdrawal of the application. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5505 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ...............................................................................
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Radiotracers for SPECT Imaging: Current Scenario and Future Prospects
    Radiochim. Acta 100, 95–107 (2012) / DOI 10.1524/ract.2011.1891 © by Oldenbourg Wissenschaftsverlag, München Radiotracers for SPECT imaging: current scenario and future prospects By S. Adak1,∗, R. Bhalla2, K. K. Vijaya Raj1, S. Mandal1, R. Pickett2 andS.K.Luthra2 1 GE Healthcare Medical Diagnostics, John F Welch Technology Center, Bangalore, India 560066 2 GE Healthcare Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, HP7 9LL, UK (Received October 4, 2010; accepted in final form July 18, 2011) Nuclear medicine / 99m-Technetium / 123-Iodine / ton emission computed tomography (SPECT or less com- Oncological imaging / Neurological imaging / monly known as SPET) and positron emission tomogra- Cardiovascular imaging phy (PET). Both techniques use radiolabeled molecules to probe molecular processes that can be visualized, quanti- fied and tracked over time, thus allowing the discrimination Summary. Single photon emission computed tomography of healthy from diseased tissue with a high degree of con- (SPECT) has been the cornerstone of nuclear medicine and today fidence. The imaging agents use target-specific biological it is widely used to detect molecular changes in cardiovascular, processes associated with the disease being assessed both at neurological and oncological diseases. While SPECT has been the cellular and subcellular levels within living organisms. available since the 1980s, advances in instrumentation hardware, The impact of molecular imaging has been on greater under- software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper. standing of integrative biology, earlier detection and charac- The biggest change in the last decade has been the fusion terization of disease, and evaluation of treatment in human of CT with SPECT, which has improved attenuation correction subjects [1–3].
    [Show full text]
  • Development and Evaluation of Radiotracers for Tumor Imaging Via
    Development and Evaluation of Radiotracers for Tumor Imaging via Positron Emission Tomography Dissertation zur Erlangung des Grades eines “Doktor rerum naturalium (Dr. rer. nat.)“ im Promotionsfach Chemie Am Fachbereich Chemie, Pharmazie und Geowissenschaften der Johannes Gutenberg-Universität Mainz Kathrin Kettenbach geboren in Mainz Mainz, im Februar 2017 Dekan: Erster Berichterstatter: Zweiter Berichterstatter: Tag der mündlichen Prüfung: 06.06.2017 Die vorliegende Arbeit wurde in der Zeit von 2013 bis 2017 am Institut für Kernchemie der Johannes Gutenberg-Universität Mainz angefertigt. „I hereby declare that I wrote the dissertation submitted without any unauthorized external assistance and used only sources acknowledged in this work. All textual passages which are appropriated verbatim or paraphrased from published and unpublished texts as well as information obtained from oral sources are duly indicated and listed in accordance with bibliographical rules. In carrying out this research, I complied with the rules of standard scientific practice as formulated in the statutes of Johannes Gutenberg-University Mainz to insure standard scientific practice.” Mainz, Februar 2017 Abstract Positron emission tomography (PET) enables the non-invasive imaging of metabolical processes in the human body. Thus, the use of radiolabeled cancer-specific targeting vectors can facilitate early diagnosis of tumors. A robust and reliable attachment of the radionuclide to the bioactive compound without major influences on its pharmacokinetic behavior is mandatory for routine PET imaging. In the herein presented work two different 18F-prosthetic groups for the radiolabeling of biomolecule-azides via click chemistry were evaluated. First, a strained prosthetic group based on (aza)dibenzocyclooctyne (DBCO) was developed to enable copper-free strain-promoted alkyne-azide cycloadditions (SPAAC) with biomolecule-azides.
    [Show full text]
  • Tauvid Integrated Review Document
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212123Orig1s000 INTEGRATED REVIEW Executive Summary Interdisciplinary Assessment Appendices NDA212123 Tauvid (flortaucipir F 18 injection) Integrated Review Table 1. Administrative Application Information Category Application Information Application type NDA Application number{s) 212123 Priority or standard Ptiority Submit date{s) 9/30/2019 Received date(s) 9/30/2019 PDUFA goal date 5/29/2020 Division/office Division oflmaging and Radiation Medicine (DIRM) Review completion date 5/27/2020 Established name Flo1taucipir F 18 (Proposed) trade name Tauvid Pharmacologic class Radioactive diagnostic agent (for PET imaging) Code name F18-AV-1451 , F18-T807, LSN3182568 Applicant Avid Radiopha1maceuticals Inc Dose form/formulation(s) Injection Dosing regimen 370 MBq (10 mCi), administered as a bolus intravenous injection Applicant proposed For positron emission tomography (PET) imaging ofthe brain to indication{s)/population{s) estimate the density and disttibution of ag~gated tau 4 nemofibrillary tangles (NFTs) !b>T m adult oatients who are bein~evaluat~d for AD (b)(4__<l>H_ •l Proposed SNOMED indication Regulatory action Approval Approved Tauvid is indicated for use with PET imaging of the brain to indication{s)/population{s) estimate the density and disttibution of aggregated tau NFTs in {if applicable) adult patients with cognitive impaiiment who are being evaluated for AD. Limitations ofUse: Tauvid is not indicated for use in the evaluation ofpatients for chronic traumatic encephalopathy (CTE) Approved SNOMED 386806002 Ihnpaired cognition (fmdiI1g) indication Integrated Review Template, version date 2019/09/25 Reference ID: 4615642 NDA212123 Tauvid (flortaucipir F 18 injection) Table of Contents Table ofTables ....................................................................................................................v Table ofFigures ...............................................................................................................
    [Show full text]
  • Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 As Novel Radiotracers for Imaging Aggregated Tau in AD
    Journal of Nuclear Medicine, published on September 28, 2017 as doi:10.2967/jnumed.117.196741 Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643 and 11C-RO6924963 as Novel Radiotracers for Imaging Aggregated Tau in Alzheimer’s Disease with Positron Emission Tomography Michael Honer1, Luca Gobbi1, Henner Knust1, Hiroto Kuwabara2,3, Dieter Muri1, Matthias Koerner1, Heather Valentine2,3, Robert F. Dannals2, Dean F. Wong2,3,4,5,6, Edilio Borroni1 1Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland 2Russell H. Morgan Department of Radiology, Division of Nuclear Medicine – PET Center, The Johns Hopkins University School of Medicine, Baltimore 3Section of High Resolution Brain PET, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore 4Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore 5Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore 6Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore Corresponding author: Dr. Michael Honer Pharma Research and Early Development (pRED) Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. 4070 Basel, Switzerland E-mail: [email protected] Running foot line: PET imaging of tau Abstract Tau aggregates and amyloid-beta (Aβ) plaques are key histopathological features in Alzheimer‘s disease (AD) and are considered as targets for therapeutic intervention as well as biomarkers for diagnostic in vivo imaging agents. This study describes the preclinical in vitro and in vivo characterization of the 3 novel compounds RO6958948, RO6931643 and RO6924963 that bind specifically to tau aggregates and have the potential to become positron emission tomography (PET) tracers for future human use.
    [Show full text]
  • Radiopharmaceuticals in Neurological and Psychiatric Disorders
    International Conference on Clinical PET-CT and Molecular Imaging (IPET 2015 ): PET-CT in the era of multimodality imaging and image-guided therapy October, 05-09, 2015, Vienna Radiopharmaceuticals in Neurological and Psychiatric Disorders Emilia Janevik Faculty of Medical Sciences Goce Delcev – Stip, Republic of Macedonia Everything that healthcare providers do has a real, meaningful impact on human life Nuclear medicine is the only imaging modality that depend of the injected radiopharmaceutical Every radiopharmaceutical that is administrated holds far more than just a radionuclide Radiopharmaceuticals want it to deliver confidence, efficiency and a higher standard of excellence. And above all, renewed hope for each patient’s future Radiopharmaceuticals for planar imaging, (SPECT), (PET), PET-CT or SPECT-CT fusion imaging PET-MRI is currently being developed for clinical application Understanding the utilization of radiopharmaceuticals for neurological and psychiatric disorders First contact…Projects related to International Atomic Energy Agency - IAEA: 1.(technical cooperation) 1995-1997 Preparation and QC od Technetium 99m Radiopharmaceuticals 99mTc - HMPAO DIAGNOSTIC APPLICATION OF SPECT RADIOPHARMACEUTICALS IN NEUROLOGY AND PSYCHIATRY The principal application areas for brain imaging include: - evaluation of brain death - brain imaging to assess the absence of cerebral blood flow - epilepsy - cerebrovascular disease - neuronal function - cerebrospinal fluid (CSF) dynamics - brain tumours Primarily technetium agents, including - nondiffusible tracers 99mTc-pertechnetate, 99mTc pentetate (Tc- DTPA) and 99mTc-gluceptate (Tc-GH) - diffusible tracers 99mTc-exametazime, hexamethylpropyleneamine oxime - (Tc-HMPAO) and 99mTc-bicisate, ethylcysteinate dimer (Tc-ECD) - Evaluation of brain death - brain imaging to assess the absence of cerebral blood flow Cerebral delivery of radiotracer Major arteries that distribute Major veins that drain blood to the brain after i.v.
    [Show full text]
  • FDA-Approved Radiopharmaceuticals
    Medication Management FDA-approved radiopharmaceuticals This is a current list of all FDA-approved radiopharmaceuticals. USP <825> requires the use of conventionally manufactured drug products (e.g., NDA, ANDA) for Immediate Use. Nuclear medicine practitioners that receive radiopharmaceuticals that originate from sources other than the manufacturers listed in these tables may be using unapproved copies. Radiopharmaceutical Manufacturer Trade names Approved indications in adults (Pediatric use as noted) 1 Carbon-11 choline Various - Indicated for PET imaging of patients with suspected prostate cancer recurrence based upon elevated blood prostate specific antigen (PSA) levels following initial therapy and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI) to help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation 2 Carbon-14 urea Halyard Health PYtest Detection of gastric urease as an aid in the diagnosis of H.pylori infection in the stomach 3 Copper-64 dotatate Curium Detectnet™ Indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients 4 Fluorine-18 florbetaben Life Molecular Neuraceq™ Indicated for Positron Emission Tomography (PET) imaging of the brain to Imaging estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline 5 Fluorine-18
    [Show full text]
  • QIBA Profile. 18F-Labeled PET Tracers Targeting Amyloid As an Imaging Biomarker
    QIBA Profile Format 20140221 1 2 18 3 QIBA Profile. F-labeled PET tracers targeting 4 Amyloid as an Imaging Biomarker 5 Version with PUBLIC COMMENTS considered 6 02May2018 7 Document generated by .\Profile Editor\ProfileTemplate.sps Page: 1 QIBA Profile Format 20140221 8 Table of Contents 9 1. Executive Summary ................................................................................................................................... 5 10 1.1 Overview ............................................................................................................................................ 5 11 1.2 Summary for Clinical Trial Use ............................................................................................................. 6 12 1.3 Intended Audiences ............................................................................................................................ 6 13 2. Clinical Context and Claims ........................................................................................................................ 7 14 2.1. Claim .................................................................................................................................................. 7 15 2.2. Considerations for claim ..................................................................................................................... 7 16 2.3. Clinical Trial Utilization........................................................................................................................ 8 17 3. Profile Activities
    [Show full text]
  • Role of AI in Theranostics: Towards Routine Personalized Radiopharmaceutical
    Role of AI in Theranostics: Towards Routine Personalized Radiopharmaceutical Therapies Julia Brosch-Lenz1, Fereshteh Yousefirizi1, Katherine Zukotynski2, Jean-Mathieu Beauregard3,4, Vincent Gaudet5, Babak Saboury6,7,8, Arman Rahmim1,9,10, Carlos Uribe10,11,* 1Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada 2Department of Medicine and Radiology, McMaster University, Hamilton, ON, Canada 3Department of Radiology and Nuclear Medicine, and Cancer Research Centre, Université Laval, Québec City, QC, Canada 4Department of Medical Imaging, and Research Center (Oncology Axis), CHU de Québec - Université Laval, Québec City, QC, Canada 5Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, Canada 6Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA 7Department of Computer Science and Electrical Engineering, University of Maryland Baltimore County, Baltimore, MD, USA 8Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA 9Department Physics, University of British Columbia, Vancouver, BC, Canada 10Department of Radiology, University of British Columbia, Vancouver, BC, Canada 11Department of Functional Imaging, BC Cancer, Vancouver, BC, Canada *Corresponding author: [email protected] Keywords: Theranostics; Radiopharmaceutical therapies; Dosimetry; Artificial intelligence; Outcome prediction; Segmentation; Registration; Quantitative Imaging Key points: 1. AI has shown promising applications in quantitative imaging required for dosimetry. 2. Segmentation of organs and tumors, the most time consuming task in the dosimetry workflow, can be automated using AI. 3. Using the theranostic approach, AI models that predict absorbed dose and therapy outcomes might play a key role in personalizing RPTs. 4. AI has significant potential to improve accuracy and reduce times for routine implementation of patient-specific dosimetry in RPTs.
    [Show full text]
  • Metabotropic Glutamate 5 Receptors: a First-In-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry
    18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry Dean F. Wong1–4, Rikki Waterhouse5, Hiroto Kuwabara1, Jongho Kim1, James R. Brasiˇ c´1, Wichana Chamroonrat1, Michael Stabins6, Daniel P. Holt1, Robert F. Dannals1, Terence G. Hamill7, and P. David Mozley7 1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; 2Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland; 3Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland; 4Department of Environmental Health Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland; 5Pfizer Inc., New York, New York; 6Vanderbilt University, Nashville, Tennessee; and 7Merck Research Laboratories, West Point, Pennsylvania measurement suggests that 18F-FPEB is suitable for quantify- Identification of safe and valid PET radioligands for metabo- ing mGluR5 in humans. tropic glutamate receptor, type 5 (mGluR5), is essential to Key Words: positron emission tomography (PET); neuroreceptors; measure changes in brain mGluR5 in neuropsychiatric disor- metabotropic glutamate receptor subtype 5 (mGluR5); 3-fluoro- ders, to confirm central mGluR5 occupancy of drug candi- 5-[(pyridin-3-yl)ethynyl]benzonitrile (FPEB); 18F-FPEB; radioligand; dates, and to guide dose selection for obtaining an optimum human radiation dosimetry therapeutic window. Here we present the results of a first-in- J Nucl Med 2013; 54:388–396 human study assessing the safety and effectiveness of a novel DOI: 10.2967/jnumed.112.107995 PET radiopharmaceutical, 18F-3-fluoro-5-[(pyridin-3-yl)ethynyl] benzonitrile (18F-FPEB), for quantifying regional brain concen- trations of mGluR5.
    [Show full text]
  • Window of Opportunity Clinical Trial Designs to Study Cancer Metabolism
    www.nature.com/bjc REVIEW ARTICLE Cancer Metabolism Window of opportunity clinical trial designs to study cancer metabolism Francesca Aroldi1 and Simon R. Lord 1 Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic assessment of a therapy of interest in tumours that are unperturbed by prior treatment. Many of the first window trials interrogated the bioactivity of drugs being repurposed for cancer treatment, in particular the anti- mitochondrial agent, metformin. In this review, we describe examples of window study designs that have been used to assess drugs that target cancer metabolism with a focus on metformin. In addition, we discuss how window studies may aid the development of molecular metabolic cancer imaging. British Journal of Cancer (2020) 122:45–51; https://doi.org/10.1038/s41416-019-0621-4 BACKGROUND pharmacodynamic activity but there will also usually be an Understanding the pharmacodynamic effects of cancer therapies emphasis on pharmacokinetic profiling. In contrast, window early in the clinical drug development pathway is key to confirm studies are typically carried out at a later stage of drug target engagement, ensure appropriate selection of patients in development, using pharmacologic drug doses, and focus on future clinical trials and identify early resistance and potential drug understanding pharmacodynamic effect. Hence, this trial design combination. Window of opportunity trials allow a drug (or other is especially appropriate when investigating the bioactivity of intervention) of interest to be given to a patient over a short drugs being repurposed for cancer treatment from other period of time, usually 2–-4 weeks, prior to the instigation of indications where the pharmacokinetic profile and safe dose level standard therapy.
    [Show full text]